Ketorolac on Posterior Thoracolumbar Spinal Fusions

Phase 4 Unknown 600 enrolled Henry Ford Health System

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine is low-dose ketorolac use in the early post-operative period (within 48 hours) provides adequate analgesia without long term adverse effect on spinal fusion rates when compared to post-operative analgesia without the use of NSAIDs.

Timeline

Start: 2017-10-03
Primary completion: 2023-12-31
Completion: 2025-12-31

Publications

Claus CF, Lytle E, Tong D, Sigler D, Lago D, Bahoura M, Dosanjh A, Lawless M, Slavnic D, Kelkar P, Houseman C, Bono P, Richards B, Soo TM. The effect of ketorolac on posterior thoracolumbar spinal fusions: a prospective double-blinded randomised placebo-controlled trial protocol. BMJ Open. 2019 Jan 21;9(1):e025855. doi: 10.1136/bmjopen-2018-025855.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ketorolac	Other / unclassified	15 mg	Intravenous

Indications

No indication recorded.